📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-30 17:12
222 analysed today
222
Today
136,230
All-time analysed
40,411
Positive
6,314
Negative
81,583
Neutral
7,854
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
33rd AGM on Aug 21; Co reports ₹42.68 Cr negative net worth and ₹17.57 Cr FY26 loss
Oxygenta Pharmaceutical has scheduled its 33rd AGM for August 21, 2026. The company reported a net loss of ₹17.57 crore for FY26, leading to a negative net worth of ₹42.68 crore and accumulated losses of ₹91.75 crore. Despite these financial challenges, the holding company, Virupaksha Organics Limited, has committed continued financial support. The agenda includes the appointment of Mr. Amireddy Venkatesu Reddy as Whole-Time Director with a proposed monthly salary of ₹6-8 lakhs.
Confidence: HIGH
What changedThe company has formalized its annual shareholder meeting and proposed a new executive leadership structure while disclosing deep financial distress.
Why it mattersThe disclosure of negative net worth and 'material uncertainty' regarding going concern highlights significant insolvency risks, mitigated only by parent company backing.
FY26 Net Loss: ₹17.57 crNegative Net Worth: ₹42.68 crAccumulated Losses: ₹91.75 crWTD Salary (Max): ₹8.00 lakh/monthLoss vs TTM Revenue: ~15.5%
📅 Short termThe stock may remain volatile as investors digest the explicit 'going concern' warnings and the depth of the net worth erosion.
📈 Long termStructural survival depends entirely on the parent company's financial commitment and a successful turnaround of the API and formulation business.
⚠ Risk flags
- Negative net worth
- Material uncertainty over going concern
- High debt of ₹110 crore
- Accumulated losses exceeding ₹90 crore
Key Highlights
Net loss of ₹17.57 crore reported for the financial year ended March 31, 2026
Negative equity/net worth of ₹42.68 crore as of March 31, 2026
Accumulated losses stand at ₹91.75 crore, raising material uncertainty about going concern
Proposed appointment of Whole-Time Director with a salary scale of ₹6,00,000 to ₹8,00,000 per month
Inventory turnover ratio improved by 104.8% YoY to 6.39 times
👀 What to Watch
Monitor the company's ability to leverage parent company support to stabilize operations and address the ₹110 crore debt burden.
Oxygenta Pharma Q1 Revenue Jumps 144% to ₹36.99 Cr; Net Loss Narrows to ₹2.10 Cr
Oxygenta Pharmaceutical reported a strong operational recovery in Q1 FY27, with revenue from operations surging 144.4% YoY to ₹36.99 Cr compared to ₹15.13 Cr in Q1 FY26. The company's net loss narrowed significantly by 65.5% to ₹2.10 Cr from a loss of ₹6.11 Cr in the previous year's corresponding quarter. During the quarter, the company secured ₹3.99 Cr in financial assistance under the government's ECLGS scheme to support liquidity. Despite the improvement, the company's balance sheet remains stressed with a negative net worth of ₹43 Cr and total debt of ₹110 Cr.
Confidence: HIGH
What changedThe company has shown a sharp increase in quarterly revenue and a significant reduction in losses, alongside securing additional government-backed credit.
Why it mattersFor a micro-cap company with negative net worth, the 144% revenue jump indicates a potential turnaround in business volume, though financial stability remains a concern due to ongoing losses.
Revenue (Q1 FY27): ₹36.99 CrNet Loss (Q1 FY27): ₹2.10 CrECLGS Loan Availed: ₹3.99 CrRevenue vs TTM Revenue: 32.7%YoY Revenue Growth: 144.4%
📅 Short termThe stock may see positive sentiment in the short term due to the substantial narrowing of losses and strong top-line growth.
📈 Long termLong-term outlook remains cautious until the company can demonstrate consistent profitability and repair its negative net worth position.
⚠ Risk flags
- Negative net worth of ₹43 Cr
- High debt of ₹110 Cr
- Continued net losses
- Gaps in identification of MSME creditors
Key Highlights
Revenue from operations grew 144.4% YoY to ₹36.99 Cr, representing 32.7% of TTM revenue.
Net loss narrowed to ₹2.10 Cr from ₹6.11 Cr in the same quarter last year.
Availed ₹3.99 Cr (₹399 lakhs) in financial assistance under the Central Government's ECLGS scheme.
Total expenses for the quarter stood at ₹39.53 Cr, still exceeding total revenue of ₹37.02 Cr.
Appointed M/s. PCR & Associates as Cost Auditors for the financial year 2026-27.
👀 What to Watch
Investors should monitor the company's ability to sustain this revenue growth to achieve operational break-even, given its negative net worth and high debt-to-equity ratio.
Oxygenta Pharma Q1 Revenue Grows 144% YoY to ₹37 Cr; Net Loss Narrows to ₹2.1 Cr
Oxygenta Pharmaceutical reported a significant YoY revenue jump of 144% to ₹36.99 Cr for Q1 FY27, although revenue declined 25% sequentially from Q4 FY26. The company's net loss narrowed to ₹2.10 Cr from ₹6.11 Cr in the year-ago period, driven by improved operational scale. However, finance costs surged nearly 4x YoY to ₹2.45 Cr, highlighting the strain of its ₹110 Cr debt. The company also utilized ₹3.99 Cr from the government's ECLGS scheme to support liquidity during the quarter.
Confidence: HIGH
What changedThe company has achieved a higher revenue base compared to the previous year and narrowed its losses, but remains dependent on emergency credit lines.
Why it mattersWhile the revenue growth is a positive sign of a potential turnaround, the company's negative net worth and rising interest costs pose significant solvency risks.
Revenue (Q1 FY27): ₹36.99 CrYoY Revenue Growth: 144.4%Net Loss (Q1 FY27): ₹2.10 CrFinance Costs: ₹2.45 CrECLGS Loan Availed: ₹3.99 CrQ1 Revenue vs TTM Revenue: ~32.7%
📅 Short termThe sharp YoY revenue growth and narrowed loss may provide some support to the stock, but the sequential decline and high interest costs will likely temper enthusiasm.
📈 Long termStructural viability remains a concern due to the negative net worth and high debt levels; long-term recovery depends on consistent profitability and deleveraging.
⚠ Risk flags
- Negative net worth (₹-43 Cr)
- High debt-to-equity ratio
- Rising finance costs
- Sequential revenue decline of 25%
Key Highlights
Revenue from operations increased 144.4% YoY to ₹36.99 Cr from ₹15.13 Cr.
Net loss narrowed to ₹2.10 Cr compared to a loss of ₹6.11 Cr in the same quarter last year.
Finance costs jumped significantly to ₹2.45 Cr from ₹0.63 Cr YoY, reflecting high interest burden.
Availed ₹3.99 Cr under the Central Government's Emergency Credit Line Guarantee Scheme (ECLGS).
Total expenses for the quarter stood at ₹39.53 Cr, still exceeding total revenue of ₹37.02 Cr.
👀 What to Watch
Monitor the company's ability to sustain quarterly revenue above ₹40 Cr to achieve operational breakeven. Investors should closely watch for any capital infusion or debt restructuring plans, given the negative net worth of ₹43 Cr.
Oxygenta Pharma Q1 Loss Narrows to ₹2.10 Cr; Revenue Grows 144% YoY
Oxygenta Pharmaceutical reported a sharp 144% YoY increase in revenue to ₹36.99 Cr for Q1 FY27. While the company remains in the red, its net loss narrowed significantly to ₹2.10 Cr from ₹6.11 Cr in the same quarter last year. The company also secured ₹3.99 Cr in financial assistance under the government's ECLGS scheme during the quarter. Despite the operational improvement, the company's financial position remains stressed with a negative net worth of ₹43 Cr and debt of ₹110 Cr.
Confidence: HIGH
What changedThe company has significantly scaled its quarterly revenue and reduced its operational losses compared to the previous year, while taking on additional government-backed debt.
Why it mattersFor a micro-cap company with negative net worth and high leverage, the narrowing of losses and top-line growth are essential indicators of a potential operational turnaround.
Revenue (Q1 FY27): ₹36.99 CrNet Loss (Q1 FY27): ₹2.10 CrECLGS Loan Availed: ₹3.99 CrRevenue vs TTM Revenue: 32.7%Debt: ₹110 Cr
📅 Short termThe market may react positively to the substantial reduction in losses and strong revenue growth, though the high finance costs remain a drag.
📈 Long termStructural concerns persist due to the negative net worth and high debt-to-equity ratio; long-term sustainability depends on consistent profitability and balance sheet repair.
⚠ Risk flags
- Negative net worth of ₹43 Cr
- High debt of ₹110 Cr
- Continued quarterly losses
- Incomplete identification of MSME creditors
Key Highlights
Revenue from operations surged 144% YoY to ₹36.99 Cr compared to ₹15.13 Cr in Q1 FY26.
Net loss narrowed by 65.6% YoY to ₹2.10 Cr from ₹6.11 Cr.
Availed ₹3.99 Cr in financial assistance under the Emergency Credit Line Guarantee Scheme (ECLGS).
Loss before tax reduced to ₹2.51 Cr from ₹8.15 Cr in the corresponding previous year quarter.
Finance costs increased to ₹2.46 Cr from ₹0.63 Cr YoY, reflecting higher debt servicing requirements.
👀 What to Watch
Investors should monitor if the company can sustain this revenue growth to achieve a break-even point, which is critical given the negative net worth. Watch for the Annual General Meeting (AGM) on August 21, 2026, for management commentary on debt reduction and capital infusion plans.
